Synapse - Paul Chapman

Results (326)

Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone

Meeting Abstract

Postow, M. A.; Kuk, D.; Adamow, M.; Carrera, C.; Wong, P.; Curran, M. A.; Friedman, C. F.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Identifying prognostic subgroups for outcomes in BRAF(V600)-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

Meeting Abstract

Larkin, J. M. G.; Ribas, A.; Flaherty, K.; McArthur, G. A.; Ascierto, P. A.; Dréno, B.; Lewis, K. D.; Chapman, P. B.; McKenna, E. F.; Zhu, Q.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)

Meeting Abstract

Friedman, C. F.; Navid-Azarbaijani, P.; Shoushtari, A. N.; Campbell, S. C.; Callahan, M. K.; Momtaz, P.; Prempeh-Keteku, N. A.; Postow, M. A.; Shames, Y.; Wolchok, J. D.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)

Meeting Abstract

Friedman, C. F.; Horvat, T. Z.; Minehart, J.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL)

Meeting Abstract

Chapman, P. B.; Sznol, M.; Lao, C.; Gonzalez, R.; Daniels, G. A.; Thompson, J. A.; Kudchadkar, R. R.; Sharfman, W. H.; Atkins, M. B.; Pavlick, A. C.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

Meeting Abstract

Yan, Y.; Robert, C.; Larkin, J.; Ascierto, P. A.; Dreno, B.; Maio, M.; Garbe, C.; Chapman, P. B.; Sosman, J. A.; Wongchenko, M. J.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies

Journal Article

Momtaz, P.; Pentsova, E.; Abdel-Wahab, O.; Diamond, E.; Hyman, D.; Merghoub, T.; You, D.; Gasmi, B.; Viale, A.; Chapman, P. B.
Oncotarget (2016)

Fulltext@MSK | Save

Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL)

Meeting Abstract

Chapman, P. B.; Sznol, M.; Lao, C. D.; Gonzalez, R.; Daniels, G. A.; Thompson, J. A.; Kudchadkar, R. R.; Sharfman, W. H.; Atkins, M. B.; Pavlick, A. C.; more...
Asia-Pacific Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Impact of key prognostic factors on long-term overall survival in BRAF(V600)-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study

Meeting Abstract

Hauschild, A.; Chapman, P. B.; Robert, C.; Larkin, J.; Haanen, J. B.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P. A.; Testori, A.; more...
Melanoma Research (2016)

Fulltext@MSK | Save

TERT promoter mutations in patients with BRAF(V600)-mutated melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Meeting Abstract

Wongchenko, M. J.; Larkin, J.; McArthur, G. A.; Ribas, A.; Dreno, B.; Chapman, P. B.; Maio, M.; Garbe, C.; Robert, C.; Lu, W.; more...
Melanoma Research (2016)

Fulltext@MSK | Save